Makana Kennedy
The Government of Uganda’s plan to invest Shs578.4 billion in the construction of the DEI Bio Pharma factory has raised eyebrows, with concerns emerging about the transparency and cost-effectiveness of the project.
According to the Budget Committee, the total cost of the project is estimated to be Shs2 trillion, significantly higher than the initial investment. Despite injecting Shs145 billion into the project, the government has yet to receive shares, prompting questions about the management of public funds.
The Attorney General is currently reviewing the documents related to the project, adding to the uncertainty surrounding its implementation.
Critics argue that the lack of transparency and oversight in the project raises serious concerns about the government’s financial management and its commitment to value for money.
There are calls for greater accountability and scrutiny of the project to ensure that public funds are being used responsibly and effectively.
As the Attorney General reviews the project documents, there is growing pressure on the government to provide answers and address the concerns raised by the Budget Committee and the public.
With the project’s total cost far exceeding initial estimates, it is essential that the government provides clear and detailed explanations regarding the use of public funds and the expected returns on investment.
Failure to do so risks undermining public trust and confidence in government projects and could have serious implications for future investment initiatives.
The government must prioritize transparency, accountability, and value for money in all its projects to ensure that taxpayer funds are used responsibly and for the benefit of all Ugandans.
